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Background
Th   ree decades of multidisciplinary research have 
resulted in detailed knowledge of the molecular patho-
genesis of Alzheimer disease (AD) [1]. We know that 
the symptoms of AD are caused by synaptic dysfunction 
and neuronal death in the areas of the brain that are 
involved in memory consolidation and other cognitive 
functions [1]. Th   is neurodegeneration is ﬁ  rmly asso  cia-
ted with aggre  gation of the 40- to 42-amino acid 
amyloid beta (Aβ) peptide into senile plaques, phos-
phorylation and aggre  ga  tion of tau proteins that form 
neuroﬁ   brillary tangles, and microglial activation that 
may be a protective response or contribute to the 
neuronal dysfunction and damage [2]. Th  e relative 
impor  tance of these processes to the clinical presen-
tation of the disease remains uncertain.
Clinical trials of novel anti-AD drugs face at least two 
major challenges. First, the new types of drug candidates 
that attack basic disease processes are likely to be most 
eﬀ  ective in early stages of the disease, before neuronal 
degeneration has become too widespread and severe [3]. 
However, clinical methods that recognize early AD are 
lacking. Second, the drug candidates may slow down the 
degenerative process without having any immediate and 
easily recognizable symptomatic eﬀ  ect [4]. Th  is makes 
evaluation of the drug eﬀ  ect diﬃ   cult. Th  eragnostic bio-
markers (that is, biomarkers that detect and monitor 
biochemical eﬀ  ects of the drug) may help solve some of 
these problems. Here, we review three pathological 
processes that are thought to be involved in the complex 
surge of AD – namely the amyloid cascade, abnormal tau 
phosphorylation, and microglial activation with neuro-
inﬂ  ammation – and the currently available biomarkers 
thought to reﬂ  ect them (Figure 1).
Core biomarkers of Alzheimer disease
It is well established that cerebrospinal ﬂ  uid (CSF) levels of 
total tau (T-tau), phospho-tau (P-tau), and the 42-amino 
acid fragment of Aβ (Aβ42) reﬂ  ect core elements of the 
AD process [3]. T-tau is a marker of cortical axonal 
degeneration and disease activity [5-7]. P-tau reﬂ  ects 
neuroﬁ  brillary pathology [8,9]. Aβ42 is a marker of plaque 
pathology [9-12]. Together, these biomarkers identify AD 
and predict AD in mild cognitive impairment (MCI) with 
a sensitivity and speciﬁ   city of 75% to 95% [3]. Th  e 
predictive power is, however, sub  optimal in general 
populations as compared with MCI cohorts because of the 
lower prevalence of incipient AD in this group [13]. Plasma 
biomarkers reﬂ  ective of patho  physiological changes in the 
AD brain are highly warran  ted, the subject of intense 
research, but unfor  tunately still lacking [3].
Drug targets
Amyloid
Experimental data, as well as longitudinal studies in 
humans, suggest that certain forms of Aβ may act as 
initiators in the disease process with potent toxic eﬀ  ects 
at the synaptic level [2]. Based on this knowledge, novel 
treat  ments aimed at inhibiting Aβ toxicity have been 
developed and are being tested in patients [14]. Th  ese 
include secretase inhibitors and modulators that aﬀ  ect 
the production of Aβ from amyloid precursor protein 
(APP), immunotherapy aimed at increasing the clearance 
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should prevent pathological build-up of the peptide in 
the brain [14].
Tau
Among the typical brain lesions in AD are neuroﬁ  brillary 
tangles that consist of abnormally phosphorylated forms 
of the microtubule-stabilizing protein tau [15]. Tau 
expres  sion is high in non-myelinated cortical axons, 
especially in the regions of the brain (such as the limbic 
cortex, including the hippocampus) which are involved in 
memory consolidation [16]. Hyperphosphorylation of tau 
causes the protein to detach from the microtubules and 
destabilizes the axons [17]. Th   is process promotes axonal 
and synaptic plasticity in the developing brain [17] but 
may be pathological in the adult brain and speciﬁ  cally 
related to a group of disorders referred to as tauopathies; 
this group includes AD and some forms of fronto-
temporal dementia [15]. Inhibiting tau phos  phory  lation 
or aggregation has been considered a promising strategy 
to slow down the neurodegeneration in AD. Drug 
candidates intervening in tau-related disease pro  cesses 
(for example, inhibitors of the tau kinase GSK3β and tau 
aggregation inhibitors) exist but are still in an early phase 
of development [14].
Microglial activation
Microglia are the resident immune cells of the central 
nervous system (CNS) [18] and are macrophages of 
myeloid lineage and invade the CNS during embryo-
genesis. Th   ese innate immune cells perform the majority 
of the immunological surveillance in the CNS. However, in 
certain conditions such as multiple sclerosis or neuro-
borreliosis, inﬁ  ltration of T cells but also B cells into the 
CNS occurs. Microglia are usually in a resting state but at 
any time may become activated in response to infection or 
injury [18]. Th   e key question of microglia in AD is whether 
the inﬂ  ammation mediated via micro  glia is beneﬁ  cial or 
not. Th   e capability of microglia to release reactive oxygen 
species, nitric oxide, interleukin-1-beta (IL-1β), and tumor 
necrosis factor-alpha (TNFα) is beneﬁ  cial in response to 
invading pathogens. However, these compounds are also 
neurotoxic and collateral damage to neurons is frequent 
during infections. Th  e same may occur in AD because 
plaques function as immunological triggers for the 
activation and recruitment of microglia, which may result 
Figure 1. Summary of candidate theragnostic biomarkers that refl  ect key drug targets in the Alzheimer disease (AD) process. Beta-
secretase inhibitors should reduce cerebrospinal fl  uid (CSF) levels of amyloid beta (Aβ) isoforms starting at the fi  rst amino acid in the Aβ sequence 
(Aβ1-X). Gamma-secretase inhibitors should reduce Aβ1-40 and Aβ1-42 and increase Aβ1-14, Aβ1-15, and Aβ1-16. Both Aβ immunotherapy and 
anti-aggregation agents might be monitored by CSF levels of Aβ1-40 and Aβ1-42. Therapy-induced Aβ degradation might be monitored by 
CSF levels of diff  erent Aβ peptides, depending on the proteolytic pathway used for degradation. Aβ effl   ux from the brain to the blood might be 
monitored by measurement of Aβ in CSF and plasma. Infl  ammatory markers in plasma and CSF as well as CSF levels of CCL2 and chitotriosidase 
activity are putative markers of microglial activity and may change in response to treatments that infl  uence microglial activity. Treatment with 
tau hyperphosphorylation inhibitors might be monitored with CSF phospho-tau (P-tau) levels. Downstream eff  ects on axonal degeneration from 
disease-modifying treatments could be monitored by using the axonal damage markers CSF total tau (T-tau) and neurofi  lament light protein (NFL). 
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been shown to clear deposits of Aβ through the Toll-like 
receptor 4 (TLR4), and AD mice with a defective TLR4 
have increased deposits of Aβ [20].
Other drug targets
Besides the three targets mentioned above, several other 
approaches are aimed at improving neural transmission 
and memory consolidation in AD. Th  ese include nerve 
growth factor gene therapy, stimulation of nicotinergic 
acetylcholine receptors by varenicline, protein kinase C 
activation by bryostatin 1, and many more [21]. 
Th   eragnostic biomarkers for each of these drugs may be 
diﬀ  erent from those reviewed below and are speciﬁ  cally 
related to the mode of action of the drug.
Theragnostic biomarkers
General issues
Th   eragnostic markers have accelerated the development 
of treatments in some types of cancer, HIV infection, 
atherosclerosis, and multiple sclerosis, and cancer-
speciﬁ   c fusion transcripts or mutations, viral load, 
plasma levels of low-density lipoprotein cholesterol, and 
brain MRI (magnetic resonance imaging) white matter 
lesion burden, respectively, have been used to ascertain 
that the drug candidate is beneﬁ  cial [22]. Th  ese  examples 
indicate that theragnostic markers may be useful in 
evaluating novel therapeutics also in AD. Furthermore, 
such studies may help to bridge the gap between animal 
studies that are poor at predicting treatment success in 
humans and large clinical trials [1]. Sometimes, these 
types of bio  markers are referred to as surrogate markers 
of patho  genic processes. However, the term surrogate 
marker often indicates a marker that is (i) a validated 
substitute for a clinically meaningful endpoint and (ii) 
expected to predict the eﬀ  ect of therapy [23,24]. Th  is 
deﬁ   nition goes beyond a mere correlation between a 
laboratory measure    ment and a clinical outcome or a 
pathogenic process since a fully validated surrogate 
marker also requires proof that intervention on the 
surrogate marker predicts the eﬀ   ect on the clinical 
outcome [25]. If applied in full by regulatory authorities, 
very few biomarkers in medicine live up to these 
requirements, which may obstruct implementation of 
surrogate biomarkers in large-scale clinical trials. 
However, this circumstance does not hinder the use of 
non-validated surrogate markers when deciding upon the 
most promising drug candidates in early stages of drug 
development. Rather, this approach is advocated by the 
US Food and Drug Administration [26].
Are they useful?
To date, only preliminary reports suggest that CSF bio-
markers may be useful in detecting and monitoring 
biochemical eﬀ   ects of novel drugs against AD. With 
regard to biomarkers for amyloid pathology, the many 
factors that inﬂ  uence steady-state levels of Aβ in CSF 
(production, aggregation, enzymatic clearance, and bi-
directional transport across the blood-brain barrier) 
make it diﬃ     cult to predict what diﬀ  erent  amyloid-
targeting treatment paradigms might do to CSF Aβ 
concen  trations. In fact, any treatment-induced change to 
an amyloid-related biomarker which is informative with 
respect to clinical outcome would be a major step forward. 
So far, data from animal studies show that γ-secretase 
inhibitor treatment results in a reduction in cortical, CSF, 
and plasma levels of Aβ [27,28]. Similarly, treatment of 
monkeys with a BACE1 inhibitor reduced the CSF levels of 
Aβ42, Aβ40, and β-sAPP [29]. Other promising 
biomarkers that are closely linked to the amyloidogenic 
process in AD are CSF BACE1 (the major β-secretase) 
concentration and activity, CSF levels of α- and β-cleaved 
soluble APP, and Aβ oligomers [30-32]. Th  ese  biomarkers 
appear to provide information of limited diagnostic 
usefulness but may turn out to be important for identifying 
treatment eﬀ  ects of drugs that are meant to inhibit β-
secretase or break up amyloid aggregates.
In patients with AD, it is uncertain how CSF Aβ42 may 
respond to treatment with eﬃ   cacious anti-Aβ drugs. A 
phase IIa study of the Aβ clearance-enhancing compound 
PBT2 showed a signiﬁ  cant dose-dependent reduction in 
CSF Aβ42 levels during treatment [33]. Data from a clinical 
study on the amyloid-targeting drug phenserine also 
showed changes in CSF Aβ levels in response to treatment 
[34]. However, in the interrupted phase IIa AN1792 trial of 
active immunization against Aβ, no signiﬁ  cant treatment 
eﬀ  ect on CSF Aβ42 was found [35]. A clinical study on γ-
secretase inhibitor treatment also failed to detect any eﬀ  ect 
on CSF Aβ42 levels [36]. Nevertheless, when the eﬀ  ect of 
this drug on Aβ produc  tion rate by the use of a stable 
isotope-labeling kinetic tech  nique was evaluated, a clear 
inhibitory eﬀ  ect of γ-secretase inhibition on Aβ production 
was identiﬁ   ed [37]. Recent data show that shorter Aβ 
peptides in CSF – namely Aβ1-14, Aβ1-15, and Aβ1-16 – 
represent a novel APP-processing pathway [38] that is 
upregulated in a dose-dependent manner in response to γ-
secretase inhibition [39].
Given longitudinal studies of conditions involving 
acute neuronal injury [40] and data from the interrupted 
phase IIa AN1792 trial [35], T-tau should decrease 
toward normal levels if a treatment is successful in inhi-
bit  ing the neurodegenerative process in AD. Th  e same 
may be expected for P-tau, as suggested by two recent 
pilot studies on memantine [41,42].
Currently, there are no established CSF biomarkers for 
microglial activation which could be used as theragnostic 
markers in trials aimed at inhibiting, boosting, or modu-
lating microglial activity in AD. Chemokine (C-C motif) 
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protein-1, or MCP-1) and chitotriosidase are ﬁ  rmly 
associated with macrophage activation in the periphery 
[43,44] and may be considered promising markers of 
microglial activation in the CNS, but studies in relation 
to AD are scarce [45]. However, several biomarkers for 
general inﬂ   ammation exist. Pilot studies showed 
increased CSF levels of transforming growth factor-beta 
(TGFβ) in AD as compared with controls [46,47]; this 
result was recently conﬁ   rmed in a meta-analysis of 
cytokines in AD [48]. Other classical markers such as 
IL-1β, IL-6, and TNFα were not altered in the CSF of 
patients with AD. Th   e plasma levels of several cytokines 
such as IL-1β, IL-6, IL-12, IL-18, TNFα, and TGFβ – but 
not IL-4, IL-8, IL-10, interferon-γ, or C-reactive protein – 
were increased in AD. Together, these data argue for an 
inﬂ  ammatory component in AD. However, the results of 
anti-inﬂ   ammatory therapy in AD have been contra-
dictory [49]. As explained above, the link between 
inﬂ   am  m  ation and other core disease processes in AD 
remains elusive.
Concluding remarks
Th  eoretical reasoning suggests that theragnostic bio-
markers could play a major role in drug development 
against AD, but, admittedly, the body of literature 
supporting this view is limited at present. We know quite 
a lot about central pathogenic features of the disease, and 
several biomarkers that monitor these features exist. A 
number of phase 0-I clinical trials indicating small but 
statistically signiﬁ  cant eﬀ  ects on theragnostic biomarkers, 
mostly in relation to axonal integrity and amyloid 
pathology, have been published. Interpreting these 
biomarker results is, however, complicated by the fact 
that none of the studies was designed to detect clinical 
eﬀ  ects. Th  is  circumstance precludes analyses of whether 
the patients with biomarker changes imposed by the 
treatment were those with the clearest clinical beneﬁ  t.
Th   e recent interruption of the phase III trials 
(IDENTITY [Interrupting Alzheimer’s Dementia by 
Evalu  ating Treatment of Amyloid Pathology] and 
IDENTITY-2) of the γ-secretase inhibitor semagacestat 
(LY450139) (Eli Lilly and Company, Indianapolis, IN, 
USA) may be considered a blow to the ﬁ  eld  of 
theragnostic biomarkers. Despite compelling evidence in 
cell and animal models, as well as plasma Aβ data [36] 
and Aβ turnover rates [37] in humans, suggesting that 
the compound reduces Aβ production, cognition 
declined faster in the treatment arms compared with 
placebo. In our view, these data should spur us to 
continue developing more biomarkers for APP- and Aβ-
processing for other desired drug eﬀ   ects such as 
improvement of neural transmission as well as for 
undesired eﬀ   ects (for example, inhibition of Notch 
signaling). For another recently failed trial (tarenﬂ  urbil, 
which is supposed to act as a γ-secretase modulator), 
there were plenty of bio  marker data suggesting that the 
drug did not hit its target in the human brain [50]. Th  ese 
data could have curbed the enthusiasm to move to phase 
III and thus saved a lot of money.
Several other clinical trials on disease-modifying drug 
candidates which include biomarkers as readouts are 
currently ongoing. Th   ese trials will provide more 
evidence on whether biomarkers will be useful as tools to 
select the most promising drug candidates for phase II/
III trials for AD.
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